| Safe People | |
|---|---|
| Lead applicant organisation name | University of Birmingham |
| Safe Projects | |
|---|---|
| Project title | An observational cohort study examining the presentation and clinical pathway followed during diagnosis and treatment of refractory and unexplained chronic cough (RCC and UCC). |
| Lay summary | "Chronic cough, lasting over eight weeks, affects 10% of the UK population at some point and poses significant health challenges. Causes include asthma and gastro-oesophageal reflux disease, though many cases remain unexplained. The condition impacts patients physically and mentally, causing discomfort, urinary incontinence, and embarrassment-related mental health issues. While new treatments like speech therapy and cough reflex-targeting medications exist, access is often limited. The NHS struggles to identify and assess eligible patients due to the involvement of various healthcare providers, hindering service planning. Specialist cough clinics could help address this issue by improving access to treatment. This project seeks to use advanced data analysis techniques on hospital outpatient clinical data to identify chronic cough patients. The accuracy of the analysis will be verified by a doctor. Additionally, the study will examine healthcare usage patterns, including clinic visits and previous treatments or tests, prior to receiving chronic cough care. This approach aims to estimate the number of chronic cough patients and their healthcare service utilization, providing valuable insights to enhance treatment pathways and planning." |
| Public benefit statement | "The study aims to identify several practical benefits: • Analyze the pathways of RCC and UCC patients in the UK to model NHS costs from diagnosis to treatment, aiding service management and evaluation of cough care. • Conduct clinician interviews to optimize chronic cough product management, improving diagnostics and promoting evidence-based therapy for RCC/UCC patients in primary and secondary care. • Investigate the effectiveness of specific cough medications across primary, secondary, and tertiary care, informing real-life management. These insights may support a future NICE Health Technology Appraisal (HTA) of cough treatments." |
| Latest approval date | 19/12/2024 |
| Safe Data | |
|---|---|
| Dataset(s) name | PATHWAY Research Data Hub: PWY005 dataset |
| Safe Setting | |
|---|---|
| Access type | Data Licence Agreement between the collaborating organisations using secure and controlled data analysis environments. |
| Safe Outputs | |
|---|---|
| Link | Not yet Published |